Alpha 2.0
Login Register
» Authors » Scott Haughie

Scott Haughie

Explore the profile of Scott Haughie including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 23
Citations 236
Followers 0
Related Specialties
Pharmacology
Urology
Pulmonary Medicine
Top 10 Co-Authors
Richard Allan
Jon Ward
Steff C Lewis
Anna Crossland
Joseph C Cappelleri
Maria Sudworth
Peter W Lane
Betsy Anagnostelis
Nigel F Baker
Patrick Moneuse
Published In
J Aerosol Med Pulm Drug Deliv
J Sex Med
Hum Vaccin Immunother
BJU Int
Res Synth Methods
Affiliations
Soon will be listed here.
Recent Articles
1.
Response by Hoeper et al to Letter Regarding Article, "Randomized, Multicenter Study to Assess the Effects of Different Doses of Sildenafil on Mortality in Adults with Pulmonary Arterial Hypertension"
Hoeper M, Haughie S, Hassan T, Vogt S, Hackley S
Circulation . 2025 Jan; 151(4):e32. PMID: 39869670
No abstract available.
2.
Randomized, Multicenter Study to Assess the Effects of Different Doses of Sildenafil on Mortality in Adults With Pulmonary Arterial Hypertension
Hoeper M, Ewert R, Jansa P, Sirenko Y, Skride A, Balagtas C, et al.
Circulation . 2024 May; 149(25):1949-1959. PMID: 38752352
Background: Sildenafil, approved for pulmonary arterial hypertension (PAH), has a recommended adult dose of 20 mg TID, with a previously approved 5-mg TID dose by the US Food and Drug...
3.
Reply letter to "Vaccine effectiveness of recombinant and standard dose influenza vaccines against outpatient illness during 2018-2019 and 2019-2020 calculated using a retrospective test-negative design"
Hadigal S, Colombo L, Haughie S
Hum Vaccin Immunother . 2023 Jun; 19(2):2227034. PMID: 37344371
A recent study by Zimmerman et al. (2023) reported non-significant higher relative vaccine effectiveness of recombinant (RIV4) over the standard-dose influenza vaccines (SDIV) against outpatient illness during the 2018-19 and...
4.
Reply letter to "Immunogenicity and safety of a quadrivalent high-dose inactivated influenza vaccine compared with a standard-dose quadrivalent influenza vaccine in healthy people aged 60 years or older: a randomized Phase III trial"
Hadigal S, Colombo L, Haughie S
Hum Vaccin Immunother . 2022 Jun; 18(5):2085470. PMID: 35674507
A recent study reported that the high-dose quadrivalent influenza vaccine provided superior immunogenicity and efficacy versus the standard-dose quadrivalent vaccine in the elderly. However, we need to view these results...
5.
Performance of Multiple-Batch Approaches to Pharmacokinetic Bioequivalence Testing for Orally Inhaled Drug Products with Batch-to-Batch Variability
Burmeister Getz E, Carroll K, Christopher J, Morgan B, Haughie S, Cavecchi A, et al.
AAPS PharmSciTech . 2021 Aug; 22(7):225. PMID: 34410557
Batch-to-batch pharmacokinetic (PK) variability of orally inhaled drug products has been documented and can render single-batch PK bioequivalence (BE) studies unreliable; results from one batch may not be consistent with...
6.
Comment on: "Safety of Marketed Cancer Supportive Care Biosimilars in the U.S.: A Disproportionality Analysis Using the Food and Drug Administration Adverse Event Reporting System (FAERS) Database"
Putzke J, Haughie S, Zou K, Ranganna G
BioDrugs . 2021 Apr; 35(3):373-374. PMID: 33860919
No abstract available.
7.
Clinical Bioequivalence of Wixela Inhub and Advair Diskus in Adults With Asthma
Ng D, Kerwin E, White M, Miller S, Haughie S, Ward J, et al.
J Aerosol Med Pulm Drug Deliv . 2019 Oct; 33(2):99-107. PMID: 31634023
Wixela Inhub is a dry powder inhaler approved as a generic equivalent to Advair Diskus (fluticasone propionate [FP]/salmeterol fixed-dose combination) for patients with asthma or chronic obstructive pulmonary disease (COPD)....
8.
Equivalent Systemic Exposure to Fluticasone Propionate/Salmeterol Following Single Inhaled Doses from Advair Diskus and Wixela Inhub: Results of Three Pharmacokinetic Bioequivalence Studies
Haughie S, Allan R, Wood N, Ward J
J Aerosol Med Pulm Drug Deliv . 2019 Aug; 33(1):34-42. PMID: 31364911
Wixela Inhub was developed to deliver inhaled fluticasone propionate/salmeterol (FP/S) combination as a substitutable generic equivalent to Advair Diskus. These studies aimed to confirm the pharmacokinetic bioequivalence (BE) of FP/S...
9.
A Dose-Response Study Examining the Use of Methacholine Challenge to Demonstrate Local Therapeutic Equivalence of the Salmeterol Component of Generic Inhaled Fluticasone Propionate/Salmeterol Combination Products
Allan R, Haughie S, Ahrens R, Singh S, Ward J
J Aerosol Med Pulm Drug Deliv . 2019 Jul; 32(6):352-363. PMID: 31259673
Asthma is widely treated using inhaled corticosteroid/long-acting beta agonist (LABA) combinations, for example, fluticasone propionate/salmeterol (FPS) dry powder inhaler, marketed as Advair Diskus. Some regulators require generics to demonstrate local...
10.
A Dose-Response Study to Examine the Methodology for Demonstrating the Local Therapeutic Equivalence of the Fluticasone Propionate Component of an Orally Inhaled Combination Therapy of Fluticasone Propionate/Salmeterol Dry Powder
Allan R, Haughie S, Kerwin E, Ward J
J Aerosol Med Pulm Drug Deliv . 2019 Jul; 32(6):364-373. PMID: 31259655
Asthma is widely treated using inhaled corticosteroid/long-acting beta-agonist combinations, such as fluticasone propionate/salmeterol (FPS) dry powder inhaler. Some regulators require generic medications to demonstrate local therapeutic equivalence (LTE) for each...